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Objective: To investigate the effectiveness of an exercise intervention for decreasing fatigue
severity and increasing physical activity in individuals with pulmonary arterial hypertension
(PAH). A small, phase 2 randomized clinical trial of the effect of aerobic exercise training
on fatigue severity and physical activity in patients with idiopathic or PAH associated with
other conditions was conducted.
Methods: Twenty-four patients with PAH (24 female; age: 54.4  10.4 years; BMI:
30.8  7.2 kg/m2) participated in the study. A convenience sample was recruited in which
9% (28 of 303) of screened patients were enrolled. The project was carried out in a clinical pul-
monary rehabilitation clinic during existing pulmonary rehabilitation program sessions.
Patients with PH were randomized into a 10-week program that consisted of patient educa-
tion only or patient education plus an aerobic exercise-training regimen. Both groups received
20 lectures, two per week over the 10-weeks, on topics related to PAH and its management. The
aerobic exercise training consisted of 24e30 sessions of treadmill walking for 30e45 min per
session at an intensity of 70e80% of heart rate reserve, three days per week over the 10 weeks.3 993 9632; fax: þ1 703 993 2695.
u (A.A. Weinstein).
3 Elsevier Ltd. All rights reserved.
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Fatigue and physical activity in PAH 779Results: After 10-weeks of intervention, patients receiving aerobic exercise training plus edu-
cation reported routinely engaging in higher levels of physical activity (p< 0.05) and a decrease
in fatigue severity (p Z 0.03). Patients in the education only group did not report changes in
fatigue severity or participation in physical activity.
Conclusions: The 10-week aerobic exercise training intervention resulted in increased physical
activity and decreased fatigue in individuals with PAH.
ClinicalTrials.gov Identifier: NCT00678821.
ª 2013 Elsevier Ltd. All rights reserved.Pulmonary Arterial Hypertension (PAH) is a rare disease
which affects between 3 and 5 of every 10,000 people in
the United States.1 Overall survival in patients with PAH is
poor and ranges between 60 and 70% three years after
initial diagnosis.2 The disease has multiple etiologies and
can be either idiopathic or associated with other conditions
such as autoimmune diseases, connective tissue disease, or
sickle cell disease.3 Clinical diagnosis of PAH is made when
mean pulmonary artery pressure equals or exceeds
25 mmHg as identified by right heart catheterization.4 The
elevated pulmonary pressures result in decreased pulmo-
nary blood flow with impaired cardiorespiratory function
that ultimately progresses to right heart failure.5 Symptoms
of PAH include shortness of breath, syncope and excessive
fatigue, all of which limit patients’ ability to engage in
physical activity.6 There are currently seven FDA-approved
compounds4,7,8 available for the treatment of PAH.
Although 3-year survival remains poor, these medications
have improved the lives of patients with PAH.9
Current medications have been somewhat effective in
reducing the severity of symptoms and improving physical
functioning in patients who have PAH. However, shortness
of breath, dizziness and perceptions of excessive fatigue
typically persist despite medical treatment.6 Severe fatigue
is common and debilitating among nearly all patients with
PAH.6 The pathophysiological basis of fatigue in PAH is
complex and its precise mechanisms remain uncharac-
terized. In patients who have PAH, fatigue may be associ-
ated with primary factors, which are related to the disease
process itself, or secondary factors such as sleep distur-
bance and depression.10 The interactions among these
contributors to fatigue severity are confluent and difficult
to isolate. There has been some evidence that patients with
PAH do not routinely engage in physical activity11 and it
seems reasonable to suspect that fatigue may deter them
from participating.
Regular participation in aerobic exercise has been re-
ported to improve cardiorespiratory fitness, increase
physical activity levels, and diminish the severity of fatigue
in patients with severe illnesses. Indeed patients with heart
failure, cancer and unexplained physical symptoms12 have
benefited from participation in aerobic exercise. In pa-
tients with PAH, significant improvements in cardiorespi-
ratory fitness and the vitality and physical function domains
of HRQoL have been reported after aerobic exercise train-
ing.13e15 Only one of these studies13 used an aerobic ex-
ercise training regimen that conformed to accepted
recommendations for individuals in need of rehabilitative
exercise which means that it could be carried out in
existing, outpatient pulmonary rehabilitation settings.The purpose of this study was to determine whether 10
weeks of medically supervised, outpatient, aerobic exer-
cise training would alter severity of fatigue and participa-
tion in physical activity. It was hypothesized that this
aerobic exercise training regimen could improve patient-
reported fatigue severity and participation in physical ac-
tivity in patients with PAH.
Methods
Patients
Patients with a diagnosis of PAH were recruited from local
outpatient pulmonary hypertension and advanced lung
disease clinics between September 2009 and April 2012.
Patients with PAH were included if they were between 21
and 82 years of age, not pregnant, and tobacco free. Pa-
tients were excluded if they participated in structured
aerobic exercise three days a week for 30 min or more, if
they were classified as World Health Organization (WHO)
functional class I and could walk more than 400 m during a
6-min walk test (6 MWT), or WHO functional class IV and
could not walk more than 50 m during a 6 MWT. Additional
exclusion criteria included an FEV1/FVC ratio 65%; a his-
tory of ischemic heart disease; an ejection fraction <40% or
a documented pulmonary capillary wedge pressure 
18 mmHg; significant hepatic, renal, metabolic or mito-
chondrial dysfunctions; severe psychiatric disease; use of
beta-adrenergic blockers or antiretroviral therapies; and
any musculoskeletal or neurological condition that would
limit walking or exercise performance. PAH was diagnosed
by a resting mean pulmonary arterial pressure 25 mmHg
determined by right heart catheterization. Patients were
on stable PAH medical regimens for at least 3 months prior
to their enrollment. Signed informed consent was obtained
from all participants prior to any procedures or data
collection. This protocol was approved by the respective
Institutional Review Boards of the collaborating
institutions.
Study design
Patients who enrolled in the protocol were sequentially
assigned subject numbers that randomly corresponded to a
group receiving concurrent patient education plus aerobic
exercise training (EXE) or to a group that received only the
patient education portion of the regimen (EDU). A 2  2
sequential block randomization schema of the subject
numbers was used in an attempt to achieve and maintain
780 A.A. Weinstein et al.near-equal group symmetry throughout the study duration.
Study personnel were blind to the randomization of pa-
tients during all baseline evaluations.
Following inclusion, patients with PAH filled out ques-
tionnaires that included the Fatigue Severity Scale and the
Human Activity Profile. These questionnaires were mea-
sures of the primary variables of interest for this study,
fatigue severity and physical activity. In addition to these
self-report measures, cardiorespiratory fitness was deter-
mined by measures of symptom-limited treadmill test
endurance and peak power output and 6 MWT distance.
Following the baseline evaluations, patients were informed
of the group to which they were randomly assigned. Pa-
tients in both the EXE and EDU groups received 20, 1-h
education sessions over 10 weeks, which were identical in
content for both groups and included lectures on anatomy
and physiology, lung disease processes, medication use,
oxygen therapy, community resources, advance directives,
panic control and social well-being.
In addition to the lectures, the EXE group concurrently
participated in 24e30 sessions of medically supervised
treadmill walking for 30e45 min per session over 10-weeks.
A target exercise intensity range of 70e80% of each sub-
ject’s heart rate reserve obtained from the respective
baseline treadmill test was used to guide each exercise
training session. The target heart rate range was calculated
as: [0.7 and 0.8  (peak HR e resting HR)] þ (resting HR), in
accordance with the method of Karvonen.16 Subject’s
perceived dyspnea and exertion, oxygen saturation, and
heart rate were continuously monitored throughout the
sessions. Treadmill speed and/or inclination were adjusted
by the designated research staff to keep each subject
within or as close as possible to target heart rate range. The
cardiorespiratory fitness tests and questionnaires were
repeated immediately following the 10-week EXE and EDU
regimens.Assessments
The Fatigue Severity Scale (FSS) measures the patient’s
perception of the influence of fatigue on physical and social
functioning through patient responses to nine different
physical and social functioning situations. Scoring is based
on a Likert scale where 1 indicates a strong disagreement
and 7 a strong agreement with the statement to quantify
the perceived fatigue severity over the preceding week.
Scoring is completed by calculating the mean response to
the questions, with a score of 4 or greater indicative of
severe fatigue.17 The FSS has been shown to be a valid tool
for individuals with varying health conditions.18
The Human Activity Profile (HAP) was developed in 1982
to assess the activity level of patients in rehabilitation. The
HAP is a self-administered test validated against a
maximum oxygen consumption (VO2 max) test.
19 The
questionnaire consists of 94 questions presented in
ascending order based on metabolic demand. The list en-
compasses activities from a variety of life situations, from
social and physical functioning to activities of daily living
such as self-care and occupational-related tasks.20 For each
activity that is listed, participants were asked if they are
(1) still doing this activity, (2) have stopped doing thisactivity, or (3) never did this activity. The HAP generates
two scores, the Maximum Activity Score (MAS) and the
Adjusted Activity Score (AAS). The MAS represents the ac-
tivity still being performed that requires the highest oxygen
consumption or metabolic equivalents (METs) and is
considered a marker of an individual’s capacity for physical
activity. The AAS is calculated by subtracting the activities
no longer performed from MAS, and is a measure of an in-
dividual’s daily physical activities and tasks. Higher scores
are indicative of higher levels of physical activity.
The 6 MWTwas conducted by having subjects walk as far
as possible for 6 min on a marked course. The 6 MWT is
scored as the total distance covered in the 6-min duration
of the test. The 6 MWT is the method perhaps most
frequently used to evaluate cardiorespiratory fitness in
both the research and clinical environments in patients
with PAH. In fact, all seven of the medications currently
available for the treatment of PAH have been approved at
least in part as a result of an improvement in 6 MWT dis-
tance following their administration and sustained use.9 At
specific intervals during the 6MWT, patients reported their
ratings of perceived dyspnea.
The symptom limited treadmill exercise test was con-
ducted by having subjects walk on a treadmill with regular
increments in work rate to a target endpoint of volitional
exhaustion. Volitional exhaustion was defined as the par-
ticipants’ expressed inability to continue exercising,
despite strong encouragement to continue by the testing
staff. Treadmill tests were performed on a Trackmaster
(Full Vision, Inc., Newton, KS) motor-driven treadmill with
computer regulated adjustments in speed and inclination. A
modified Naughton protocol was followed.13 Heart rate was
measured by electrocardiogram. The resting and peak
heart rates attained during the baseline treadmill test were
used to calculate the target heart rate range during the
aerobic exercise training. Peak power output and the time
the treadmill test could be sustained were recorded as
outcome measures of cardiorespiratory fitness.
Statistical analysis
Data were analyzed using the statistical software package
SPSS version 18.0 (IBM Corporation, Somers, NY). Chi-
square and independent t-tests were used to determine
differences between the individuals randomly assigned to
the EXE versus the EDU group. To investigate the effect of
the exercise intervention on fatigue, physical activity, ex-
ercise test duration, 6 MWT distance, and peak power
output, repeated measures analyzes of variance were used
to examine the interaction between group assignment (EXE
vs EDU) and time of assessment (baseline vs. post-
intervention). If a statistically significant interaction exis-
ted, pairwise comparisons were then performed. Statistical
significance was set to p  0.05.
Results
Demographic and clinical characteristics
Twenty-nine (9.6%) of the 303 total patients screened met
the inclusion criteria without identification of an exclusion
Fatigue and physical activity in PAH 781criterion (Fig. 1). All 29 of these patients performed base-
line testing. Based on their test responses, two of these
patients were required to obtain additional medical clear-
ance prior to beginning the intervention. One patient
declined further participation while the other patient was
cleared for participation and subsequently assigned a new
subject number upon re-entry into the protocol. This pa-
tient was originally assigned a subject number corre-
sponding to EXE, but at re-entry the randomization
procedure resulted re-assignment to EDU. As such, 28 pa-
tients in total participated in either the EXE or EDU groups
(Fig. 1). Of the 14 patients allocated to the EXE group, two
patients withdrew due to changes in medication and one
withdrew due to low attendance at the exercise sessions.
One patient in the EDU group was withdrawn from the study
due to medication changes. Data for the 24 patients (EXE,
nZ 11; EDU, nZ 13) that completed the interventions was
included in the analyzes.Enrolled a
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Figure 1 Participant flow chart. (n Z 1*) represents the sameThe demographic and clinical characteristics of patients
are presented in Table 1. The PAH cohort consisted of all
female patients, ranging in age from 32 to 68 years
(54.4  10.4 years), with BMI from 17.3 to 43.6
(30.8  7.2 kg/m2). Age and BMI were not significantly
different at baseline for EXE and EDU groups (Table 1).
Groups were heterogenous and included patients with
idiopathic PAH and PAH associated with other conditions
such as scleroderma, Sjogren’s syndrome and systemic
lupus erythematosus (Table 1). Patient’s medication regi-
mens were stable for 3 months prior to beginning partici-
pation in the study and remained unchanged throughout
the study’s duration.
The exercise sessions were well attended (only one
participant was withdrawn from the study due to poor
adherence), with an attendance ranging between 24 and 30
(80e100%) sessions, and averaging 26.8  2.2 sessions. The
EXE regimen resulted in a 53  44 m increase in 6 MWTnd assigned 
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patient through the enrollment and randomization process.
Table 1 Baseline participant characteristics.
Characteristics All patients
(n Z 24)
EXE Group
(n Z 11)
EDU Group
(n Z 13)
Comparison
between groups
(P value)
Age, mean (SD), y 54.4 (10.4) 53.4 (12.4) 55.3 (8.7) 0.658
Female, no. (%) 24 (100) 11 (100) 13 (100) 0.999
Race/ethnicity, no. (%)
Black 11 (45.8) 3 (27.3) 8 (61.5) 0.273
White 9 (37.5) 6 (54.5) 3 (23.1)
Other 4 (16.7) 2 (18.2) 2 (15.4)
BMI, mean (SD), kg/m2 30.8 (7.2) 29.4 (7.0) 31.9 (7.4) 0.455
WHO/NYHA functional class, no. (%)
Class I 1 (4.2) 1 (9.1) 0 0.363
Class II 12 (50) 4 (36.4) 8 (61.5)
Class III 10 (41.6) 5 (45.4) 5 (38.5)
Class IV 1 (4.2) 1 (9.1) 0
PAH etiology, no. (%)
Idiopathic pulmonary arterial hypertension 6 (25) 2 (18.2) 4 (30.8) 0.723
Mixed connective tissue disease 1 (4.2) 0 1 (7.7)
Rheumatoid arthritis 1 (4.2) 0 1 (7.7)
Scleroderma 12 (50) 7 (63.6) 5 (38.4)
Sjogren’s syndrome 2 (8.3) 1 (9.1) 1 (7.7)
Systemic lupus erythematosus 2 (8.3) 1 (9.1) 1 (7.7)
Drug combination therapy, no. (%)
None 1 (4.2) 0 1 (7.7) 0.186
Mono therapy 7 (29.3) 5 (45.4) 2 (15.4)
Dual therapy 6 (25) 1 (9.1) 5 (38.4)
Triple therapy 9 (37.5) 5 (45.4) 5 (38.4)
Human activity profile, mean (SD)
Maximal activity score 63 (11) 58 (11) 67 (10) 0.061
Adjusted activity score 50 (15) 43 (13) 57 (14) 0.021
Fatigue severity score (FSS), mean (SD) 4.2 (1.8) 4.9 (1.6) 3.5 (1.8) 0.059
FSS score > 4, no. (%) 14 (58.3) 9 (81.8) 5 (38.4) 0.032
Cardiorespiratory fitness measures
6 MWT distance, m 396 (84) 412 (69) 383 (96) 0.418
Treadmill time to exercise intolerance, min 6.2 (1.9) 6.6 (1.8) 5.8 (2.0) 0.320
Peak power output, W 91.8 (45) 97.5 (41) 86.9 (50) 0.579
782 A.A. Weinstein et al.distance (pZ 0.003), a 2.1  0.75 min increase in symptom
limited treadmill exercise test duration (p Z 0.001), an
increase in peak power output of 25  22 W (pZ 0.003) and
no change in perceived dyspnea at the completion of the
6 MWT (0.3  2.11; p > 0.50). No significant differences in
6 MWT distance, treadmill test duration, peak power
output, or perceived dyspnea were observed following the
EDU regimen.
Concomitant with observed increases in cardiorespira-
tory fitness, patients in the EXE group reported improve-
ments in our main variables of interest, physical activity
and fatigue severity (Fig. 2). Significant increases in both
AAS (pZ 0.036) and MAS (pZ 0.022) were observed for the
EXE group following aerobic exercise training. A significant
(p Z 0.003) decrease in FSS composite score (post-
trainingZ 3.45  1.1 versus pre-training Z 4.9  1.6) was
observed after aerobic exercise training in EXE group
(Fig. 2). Patients in the EXE group reported decreases on 6
of the 9 individual FSS items (Fig. 3). A change in fatigue
severity was not observed in EDU. Nine patients in EXE had
severe fatigue at baseline, only 2 of the 9 patients originallyreporting severe fatigue continued to report it after the
aerobic exercise training regimen (p Z 0.03).Discussion
Patients in the EXE group had improved cardiorespiratory
fitness13 concomitant with increased participation in phys-
ical activity and decreased fatigue severity, following the
aerobic exercise-training regimen compared to baseline.
Not only was overall fatigue severity diminished, fewer of
these patients reported experiencing fatigue severe enough
to interfere with physical or social functioning following
aerobic exercise training. This finding may help to explain
improvements in HRQoL reported in previous exercise in-
terventions.13,15 The aerobic exercise regimen used in this
study was similar in intensity, session duration, and fre-
quency of participation to programs known to improve
cardiorespiratory fitness in the general population. In-
creases in cardiorespiratory fitness observed here were in
agreement with previous reports.13e15 Results of this study
Figure 2 Change in fatigue severity scale (FSS) and human
activity profile (HAP) scores in response to 10-weeks of aerobic
exercise training plus education (EXE) or education alone
(EDU). *p < 0.05 for difference in change score between EXE
group versus EDU group. AAS is the adjusted activity score on
the HAP and MAS is the maximal activity score on the HAP.
Fatigue and physical activity in PAH 783suggest that this type of exercise training is likely to be
sufficient for improving cardiorespiratory fitness,
decreasing the severity of fatigue, and increasing partici-
pation in physical activity in patients with PAH of various
etiologies.
Previous information regarding the effect of an aerobic
exercise intervention on fatigue severity and participation
in physical activity is lacking in patients with PAH. Some
earlier studies have suggested that aerobic exercise
training may be safe and efficacious for patients with PAH,
but measures of fatigue or physical activity were not
included among their outcome variables.14,15,21 The long-Figure 3 Item analysis of the fatigue severity scale (FSS) for
the aerobic exercise training plus education group. *p < 0.05
for baseline versus post-intervention score (10-weeks score) on
the individual items of the FSS.term effects of aerobic exercise training on PAH survival
have not been determined and this may be a next logical
step in examining the efficacy of rehabilitative aerobic
exercise training in patients with PAH. Moreover, durability
of the effect of aerobic exercise training on cardiorespi-
ratory fitness, fatigue severity and physical activity, and
the feasibility of long-term compliance with continued
participation in an aerobic exercise training regimen have
yet to be determined.
In this study, the PAH cohort was heterogenous with
respect to etiology. The cohort included patients with
idiopathic PAH as well as those with PAH associated with
autoimmune diseases such as scleroderma, systemic lupus
erythematosus, and mixed connective tissue disease.
Decreased cardiorespiratory fitness and physical activity,
and increased fatigue severity are associated with each of
these conditions independently, as well as with idiopathic
PAH. In some patients with these autoimmune conditions
who do not have PAH, aerobic exercise training has been
reported to improve cardiorespiratory fitness, decrease
fatigue, and increase physical activity.22e25 The current
study demonstrates the effectiveness of aerobic exercise
training for reducing fatigue severity and increasing phys-
ical activity even when PAH occurs secondarily to an un-
derlying connective tissue disease.Limitations
The current investigation included a small sample, which
increases the likelihood of Type II error. Statistical signifi-
cance was found in the main variables of interest and thus
Type II error was minimized in this investigation. Although
heterogenous, the small, convenience sample precludes
widespread generalization of the results of this study.
Physical activity was self-reported. Individuals in the EXE
group may have been sensitized to physical activity
following their participation in an exercise trial and
therefore, may have been more likely to report their
physical activity than the EDU group. Finally, all the par-
ticipants were females and classified as having WHO Group
1 PAH. Further work is needed to determine if these results
would be applicable to men or to patients with PH who are
in WHO Groups 2 through 5.Clinical implications
The results of this study indicate that exercise training may
decrease the severity of fatigue and increase physical ac-
tivity in patients who have idiopathic PAH or PAH associated
with other conditions. These findings expand the available
information regarding the benefits of medically supervised
aerobic exercise training in female patients with Group
1 PAH, underscoring its potential importance as an adjunct
therapy. The aerobic exercise training regimen used in this
study is similar to one often recommended to the general
population or prescribed for patients participating in car-
diac and pulmonary rehabilitation exercise programs. The
results demonstrate that the positive effects of aerobic
exercise training may extend beyond measures of cardio-
respiratory fitness.
784 A.A. Weinstein et al.Conclusion
Ten weeks of thrice weekly, medically supervised, tread-
mill walking, at 70e80% of HRR, for 30e45 min per week,
was found to reduce patient-reported fatigue, increase
participation in physical activity and improve cardiorespi-
ratory fitness and 6 MWT distance in Group 1 PAH. The
regimen that was used was easily incorporated into an
existing clinical pulmonary rehabilitation program. Overall,
the results support the use of aerobic exercise training as
an adjunct to existing medical regimens in patients with
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